Ziopharm to conduct $50 million public offering of stock via JPMorgan

Deal funds development of synthetic biology, small-molecule candidates

By Toni Weeks

San Luis Obispo, Calif., Oct. 22 - Ziopharm Oncology, Inc. plans to conduct an underwritten public offering of stock to raise $50 million. The deal has a 30-day, $7.5 million greenshoe option.

J.P. Morgan Securities LLC will act as bookrunner for the offering.

Proceeds will be used for development of the company's drug candidates, including its synthetic biology candidates and small-molecule candidates, and for general corporate and working capital purposes.

Boston-based Ziopharm is a biotechnology company employing novel gene expression and control technology to deliver DNA for the treatment of cancer.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.